Generic Name and Formulations:
Pimozide 1mg, 2mg; scored tabs.
Indications for ORAP:
Motor and phonic tics of Tourette's disorder unresponsive to standard treatment that severely compromise development or daily life function.
Initially 1–2mg/day in divided doses; may increase every other day to max 0.2mg/kg per day not to exceed 10mg/day.
<12yrs: not recommended. ≥12yrs: Initially 0.05mg/kg once daily at bedtime; may increase every third day to max 0.2mg/kg, not to exceed 10mg/day.
Simple tics or tics not associated with Tourette's disorder. Drugs that may cause tics (eg, pemoline, methylphenidate, amphetamines) or prolong the QT interval (eg, phenothiazines, tricyclic antidepressants, antiarrhythmics, dofetilide, sotalol, quinidine, other Class IA or III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, tacrolimus, ziprasidone, others). Congenital long QT syndrome. History of cardiac arrhythmias. Hypokalemia. Hypomagnesemia. Severe CNS depression or comatose states. Concomitant CYP3A4 inhibitors (eg, macrolides antibiotics, azole antifungals, protease inhibitors, nefazodone, zileuton, fluvoxamine, sertraline), citalopram, escitalopram.
Renal or hepatic impairment. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. History of seizures or EEG abnormalities. Monitor ECG at baseline and periodically (esp. during dose adjustment). Correct hypokalemia before starting. Avoid abrupt cessation. May have tumorigenic potential. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. May be potentiated by CYP1A2 inhibitors. Potentiates CNS depression with alcohol, analgesics, other CNS depressants. Caution with anticonvulsants. Avoid grapefruit juice.
Sedation, anticholinergic effects, extrapyramidal symptoms, tardive dyskinesia, ECG changes, neuroleptic malignant syndrome, hyperpyrexia; leukopenia/neutropenia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed